The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000, China
NCT Number: NCT07551570
This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal renal function.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Bengbu, Anhui, 233000, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral single dose
Time frame: Day1-Day3
Time frame: Day1-Day3
Jiangsu vcare pharmaceutical technology co., LTD
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07217886
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsNCT06911320
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsNCT03896750
Actinomycetales Infections, Bacterial Infections
Miami, Florida, United States
View Trial DetailsNCT03289208
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Tokyo, Japan
View Trial Details